Shares Magazine
$127.64+1.73 (+1.37%)24 Mar 2025, 19:13
Jump to:
Abbott Laboratories Fundamentals
| Company Name | Abbott Laboratories | Last Updated | 2025-03-24 |
|---|---|---|---|
| Industry | Medical Devices | Sector | Healthcare |
| Shares in Issue | 1.734 bn | Market Cap | $221.37 bn |
| PE Ratio | 16.48 | Dividend per Share | $2.20 |
| Dividend Yield | 1.78 | Dividend Cover | 3.47 |
| EPS | $7.64 | EPS Growth (%) | 1.32 |
| PEG | 0 | DPS Growth (%) | 0.0784 |
| Debt Ratio | 0.1845 | Debt Equity Ratio | 0.2837 |
| Asset Equity Ratio | 1.6996 | Cash Equity Ratio | 0.1663 |
| Quick Ratio | 1.2335 | Current Ratio | 1.67 |
| Price To Book Value | 4.5809 | ROCE | 0 |
Abbott Laboratories Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|---|---|---|---|---|
| Interim | 2025-04-14 | 2025-05-15 | USD | 0.5900 | |
| Prelim | 2025-01-15 | 2025-02-14 | USD | 0.5900 | |
| Interim | 2024-10-15 | 2024-11-15 | USD | 0.5500 | |
| Interim | 2024-07-15 | 2024-08-15 | USD | 0.5500 | |
| Interim | 2024-04-12 | 2024-05-15 | USD | 0.5500 | |
| Prelim | 2024-01-11 | 2024-02-15 | USD | 0.5500 | |
| Interim | 2023-10-12 | 2023-11-15 | USD | 0.5100 | |
| Interim | 2023-07-13 | 2023-08-15 | USD | 0.5100 | |
| Interim | 2023-04-13 | 2023-05-15 | USD | 0.5100 | |
| Prelim | 2023-01-12 | 2023-02-15 | USD | 0.5100 | |
| Interim | 2022-10-13 | 2022-11-15 | USD | 0.4700 | |
| Interim | 2022-07-14 | 2022-08-15 | USD | 0.4700 | |
| Interim | 2022-04-13 | 2022-05-16 | USD | 0.4700 |
Abbott Laboratories Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | $10.66 bn | $10.15 bn | $9.16 bn |
| Intangible Assets | $29.75 bn | $32.49 bn | $33.25 bn |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $57.76 bn | $50.54 bn | $49.21 bn |
| Stocks | $6.19 bn | $6.57 bn | $6.17 bn |
| Debtors | 0 | 0 | 0 |
| Cash & Equivalents | $7.97 bn | $7.28 bn | $10.17 bn |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $81.41 bn | $73.21 bn | $74.44 bn |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | $14.16 bn | $13.84 bn | $15.49 bn |
| Creditors after 1 year | $19.36 bn | $20.55 bn | $22.04 bn |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $33.51 bn | $34.39 bn | $37.53 bn |
| Net assets | $47.90 bn | $38.83 bn | $36.91 bn |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | $25.15 bn | $24.87 bn | $24.71 bn |
| Share Premium | 0 | 0 | 0 |
| Profit / Loss | $7.01 bn | $6.66 bn | $8.31 bn |
| Other Equity | $47.66 bn | $38.60 bn | $36.69 bn |
| Preference & Minorities | $237.00 m | $224.00 m | $219.00 m |
| Total Capital Employed | $47.90 bn | $38.83 bn | $36.91 bn |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | $0.22 | $0.27 | $0.30 |
| Debt-to-Equity | $0.28 | $0.38 | $0.42 |
| Assets / Equity | 1.6996 | 1.6996 | 1.6996 |
| Cash / Equity | 0.1663 | 0.1663 | 0.1663 |
| EPS | $7.66 | $3.30 | $3.94 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | $8.56 bn | $7.26 bn | $9.58 bn |
| Cashflow before financing | $3.15 bn | $170.00 m | $1.95 bn |
| Increase in Cash | $720.00 m | -$2.99 bn | $83.00 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | $41.95 bn | $40.11 bn | $43.65 bn |
| Cost of sales | $18.71 bn | $17.98 bn | $19.14 bn |
| Gross Profit | $23.24 bn | $22.13 bn | $24.51 bn |
| Operating Profit | $6.83 bn | $6.48 bn | $8.36 bn |
| Pre-Tax profit | $7.01 bn | $6.66 bn | $8.31 bn |
Abbott Laboratories Company Background
| Sector | Healthcare |
|---|---|
| Activities | Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States. |
| Latest Interim Date | 18 Jul 2024 |
| Latest Fiscal Year End Date | 22 Jan 2025 |
Abbott Laboratories Directors
| Appointed | Name | Position |
|---|---|---|
| 2020-04-24 | Mr. Edward M. Liddy | Director |
| 2017-07-21 | Mr. Eric S. Fain,M.D. | Senior Vice President |
| 2022-04-29 | Mr. Glenn F. Tilton | Director |
| 2023-02-28 | Mr. John M. Capek | EXECUTIVE VICE PRESIDENT |
| 2015-02-27 | Mr. John C. Landgraf | Executive Vice President |
| 2017-02-28 | Mr. Michael J. Warmuth | Executive Vice President |
| 2017-07-07 | Mr. Michael T. Rousseau | Pres., Cardiovas. & Neuromod. |
| 2016-02-29 | Mr. Richard W. Ashley | Executive Vice President |
| 2023-02-28 | Mr. Randel W. Woodgrift | SENIOR VICE PRESIDENT |
| 2019-04-26 | Mr. Samuel C. Scott, III | Director |
| 2024-12-31 | Dr. Robert J. Alpern,M.D. | Director |
| 2019-04-23 | Mr. Stephen R. Fussell | Executive Vice President |
| 2022-04-29 | Mr. William A. Osborn | Director |
| 2016-07-29 | Mr. Thomas C. Freyman | Executive Vice President |
| 2016-04-29 | Mr. W. James Farrell | Director |
| 2017-07-01 | Ms. Heather L. Mason | Executive Vice President |
| 2023-02-28 | Mr. Michael J. Dale | SENIOR VICE PRESIDENT |
| 2020-12-04 | Ms. Phebe N. Novakovic | Director |
| 2021-04-23 | Ms. Roxanne S. Austin | Director |
| 2020-04-21 | Mr. Jaime Contreras | Senior Vice President |
| 2024-12-31 | Mr. John G. Stratton | Director |
| 2025-02-28 | Ms. Mary K. Moreland | EXECUTIVE VICE PRESIDENT |
| 2024-05-10 | Mr. Robert E. Funck, Jr | EXECUTIVE VICE PRESIDENT |
| 2024-04-26 | Ms. Nancy Mckinstry | Director |
| 2021-11-10 | Mr. Miles D. White | Director, EXECUTIVE CHAIRMAN |
| 2019-05-23 | Mr. Brian J. Blaser | Executive Vice President |
| 2013-09-17 | Mr. David A. Forrest | Senior Vice President |
| 2024-04-26 | Mr. Michael G. O’Grady | Director |
| 2025-03-06 | Ms. Lisa D. Earnhardt | EVP AND GROUP PRESIDENT |
| 2024-04-26 | Dr. Sally E. Blount, PhD | Director |
| 2025-02-28 | Mr. Hubert L. Allen | EXECUTIVE VICE PRESIDENT, GC |
| 2015-02-27 | Mr. Murthy V. Simhambhatla | Senior Vice President |
| 2014-05-23 | Ms. Katherine C. Doyle | Senior Vice President |
| 2015-04-01 | Mr. Charles D. Foltz | Senior Vice President |
| 2024-12-31 | Mr. Michael F. Roman | Director |
| 2015-02-27 | Georges H. DeVos | Senior Vice President |
| 2016-07-01 | Mr. Jean-Yves Frederic Georges Andre Pavee-Callu | Senior Vice President |
| 2025-02-28 | Mr. Robert B. Ford | Director, CHAIRMAN AND CEO |
| 2025-02-28 | Mr. Daniel Gesua Sive Salvadori | EVP AND GROUP PRESIDENT |
| 2021-04-27 | Mr. Roger M. Bird | SENIOR VICE PRESIDENT |
| 2017-04-28 | Mr. Deepak S. Nath | Senior Vice President |
| 2024-04-26 | Ms. Michelle A. Kumbier | Director |
| 2020-02-28 | Mr. Brian B. Yoor | Executive Vice President & CFO |
| 2021-11-15 | Mr. Andrew H. Lane | EXECUTIVE VICE PRESIDENT |
| 2023-02-28 | Mr. Jared L. Watkin | SENIOR VICE PRESIDENT |
| 2025-02-28 | Mr. John A. Mccoy, Jr | VICE PRESIDENT AND CONTROLLER |
| 2016-02-19 | Mr. Thomas G. Frinzi | Senior Vice President |
| 2023-02-28 | Mr. Joseph J. Manning | EXECUTIVE VICE PRESIDENT |
| 2018-12-31 | Mr. Sean Shrimpton | Senior Vice President |
| 2019-03-31 | Ms. Sharon J. Bracken | Senior Vice President |
| 2021-02-26 | Mr. Charles R. Brynelsen | SENIOR VICE PRESIDENT |
| 2023-02-28 | Mr. Michael J. Pederson | SENIOR VICE PRESIDENT |
| 2023-02-28 | Mr. Alejandro D. Wellisch | SENIOR VICE PRESIDENT |
| 2023-02-28 | Mr. Sammy Karam | SENIOR VICE PRESIDENT |
| 2021-04-01 | Mr. Christopher J. Scoggins | SENIOR VICE PRESIDENT |
| 2025-02-28 | Ms. Andrea F. Wainer | RETIRED EVP |
| 2023-02-28 | Mr. John F. Ginascol | EXECUTIVE VICE PRESIDENT |
| 2024-04-26 | General Darren W. McDew, U.S.A.F. (Ret.) | Director |
| 2025-02-28 | Mr. Philip P. Boudreau | EVP AND CFO |
| 2023-02-28 | Mr. Gregory A. Ahlberg | SENIOR VICE PRESIDENT |
| 2023-02-28 | Ms. Julie L. Tyler | SENIOR VICE PRESIDENT |
| 2025-02-28 | Mr. Louis H. Morrone | EXECUTIVE VICE PRESIDENT |
| 2023-02-28 | Mr. Christopher J. Calamari | SENIOR VICE PRESIDENT |
| 2024-12-31 | Ms. Patricia P. Gonzalez | Director |
| 2023-02-28 | Mr. Fernando Mateus | SENIOR VICE PRESIDENT |
| 2025-03-03 | Mr. Eric Shroff | Senior Vice President |
Abbott Laboratories Contact Details
| Company Name | Abbott Laboratories |
|---|---|
| Address | 100 Abbott Park Road, Abbott Park, 60064-6400 |
| Telephone | +1 224 6676100 |
| Website | https://www.abbottinvestor.com |
Abbott Laboratories Advisors
| Auditor | Ernst & Young LLP |
|---|
| Auditor | Deloitte & Touche LLP |
|---|
| Solicitor | Mayer Brown LLP |
|---|
| Solicitor | Baker & McKenzie LLP |
|---|
| Auditor | Deloitte & Touche LLP |
|---|
| Auditor | Arthur Andersen LLP |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Pershing Square Holdings LTD | 3,906.00 | 3.94 |
| Asos PLC | 312.40 | 3.51 |
| Baillie Gifford Us Growth Trust PLC | 237.00 | 3.49 |
| Bellway PLC | 2,412.00 | 3.34 |
| Wizz Air Holdings PLC | 1,705.00 | 3.33 |
| Polar Capital Technology Trust PLC | 317.00 | 3.26 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Energean PLC | 815.50 | -6.53 |
| Oxford Nanopore Technologies PLC | 104.30 | -6.46 |
| Aston Martin Lagonda Global Holdings PLC | 72.75 | -4.65 |
| Harbour Energy PLC | 195.45 | -4.47 |
| Vodafone Group PLC | 72.00 | -4.43 |
| Discoverie Group PLC | 572.00 | -3.70 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.